| Today’s Big NewsMar 11, 2025 |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
| By Angus Liu After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart—only once a year. |
|
|
|
By Darren Incorvaia Funding granted to researchers by the National Institutes of Health powered $94.58 billion in economic activity across the U.S. in 2024, according to an annual report published March 11 by biomedical research advocacy organization United for Medical Research. The number was a $1.68 billion increase from the prior year. |
By Kevin Dunleavy At its sprawling manufacturing complex in Durham, N.C., Merck has opened a new $1 billion plant slated to produce megablockbuster HPV vaccine Gardasil. |
By James Waldron Pfizer and Arvinas’ estrogen receptor degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy still has a path to regulators. |
By Conor Hale Illumina also lowered its annual financial forecast, as it plans to deal with a loss of revenue from China after the country's retaliation for U.S. tariffs. |
By Fraiser Kansteiner For his work in 2024, AbbVie helmsman Robert Michael—who took over the CEO post from Richard Gonzalez on July 1—collected roughly $18.5 million in total pay. The figure was a $4 million jump over the sum he earned in 2023, when he was the Chicago drugmaker's chief operating officer. |
By James Waldron Coherus BioSciences will see its workforce shrink once again as a result of the recent sale of its Neulasta biosimilar to Accord BioPharma. |
By Conor Hale Siemens Healthineers aims to bring photon-counting technology to single-source CT scanners aimed at ERs and other facilities. |
By Nick Paul Taylor Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. |
By Nick Paul Taylor Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly appointed chief commercial officer, Kearney will oversee preparations to launch a rival to AbbVie’s age-related blurry near vision product Vuity. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PTLearn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
